Contents

Search

pomalidomide (Pomalyst)

Indications: - treatment of multiple myeloma after progression of disease with lenalidomide & bortezomib treatment Contraindications: - pregnancy Adverse effects: - neutropenia, anemia, thrombocytopenia - venous thromboembolism [2] - fatigue, weakness - constipation, diarrhea - upper respiratory tract infections - back pain - fever Mechanism of action: - modulates immune system - the other 2 drugs in this class, lenalidomide & thalidomide, are also angiogenesis inhibitors

General

antineoplastic immunomodulator

Database Correlations

PUBCHEM cid=134780

References

  1. FDA News Release: Feb. 8, 2013 FDA approves Pomalyst for advanced multiple myeloma ww.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm338895.htm
  2. Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022